Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...

Finally, the number of opportunities in the biosimilars space is very high — there are more than 300 biologics in the market, ...

The global contract development and manufacturing organization ​ (CDMO), Samsung Biologics, announced this week that it has ...

From developing treatments for Ebola to mastering karate with her daughters, Dr. Helen Harrington’s journey is one of ...

Steritas LLC, a Boston-based company committed to improving care for patients treated with steroids, has announced a multi-year licensing agreement with argenx, a global leader in immunology. The ...

From discovering her knack for chemistry in high school to proving her expertise in male-dominated spaces, Tran Pham has built a dynamic career in biopharma. Now the Global market development manager ...

PTC Therapeutics has received FDA approval for a gene therapy to treat AADC deficiency, a rare genetic disorder that impairs the normal function of neurons. The FDA has granted accelerated approval to ...